Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BLISOVI 24 FE vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and drospirenone; primarily suppresses gonadotropins (FSH, LH) via negative feedback, preventing ovulation. Drospirenone has anti-mineralocorticoid and anti-androgenic activity.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women ≥14 years (only if desiring contraception),Treatment of premenstrual dysphoric disorder (PMDD) in women of reproductive age
Prevention of pregnancy
One tablet orally once daily for 24 weeks, followed by placebo tablets for 4 weeks; each tablet contains 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol for 21 days, then 0.01 mg ethinyl estradiol for 3 days, then 2 tablets of 75 mg ferrous fumarate for 5 days.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Drospirenone: 25-33 hours; Ethinyl estradiol: 13-24 hours; steady-state achieved after 10 days.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Ethinyl estradiol undergoes hydroxylation via CYP3A4 and conjugation (glucuronidation, sulfation); drospirenone is metabolized primarily via CYP3A4 and to a lesser extent via CYP1A1 and CYP2C9.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal: 30-40% as drospirenone metabolites, 20-30% as ethinyl estradiol metabolites; fecal: 40-50% as drospirenone metabolites, 30-40% as ethinyl estradiol metabolites; biliary: minimal.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Drospirenone: 95-97% bound to albumin; Ethinyl estradiol: 98% bound to albumin and SHBG.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Drospirenone: 4 L/kg; Ethinyl estradiol: 2-4 L/kg; indicates extensive tissue distribution.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: Drospirenone ~76%; Ethinyl estradiol ~45% (first-pass metabolism reduces absolute bioavailability).
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (GFR <30 m L/min/1.73 m²) due to potential fluid and electrolyte disturbances.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in acute hepatic disease, hepatic adenomas, or impaired liver function (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh A), use with caution and monitor liver function; dose adjustment not specifically defined.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally once daily for 24 weeks followed by placebo for 4 weeks.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for use in postmenopausal women. No specific geriatric dose studies; use not recommended in elderly due to lack of indication.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives (COCs). Risk increases with age (especially in women >35 years) and with number of cigarettes smoked. Women over 35 who smoke should not use COCs.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thrombotic disorders and cardiovascular events (including VTE, MI, stroke),Liver disease (including hepatic adenoma or active hepatitis),Hypertension (especially new-onset or uncontrolled),Carbohydrate and lipid metabolism effects,Headache (including migraine with focal neurological symptoms),Bleeding irregularities (e.g., breakthrough bleeding, amenorrhea),Depression,Gallbladder disease,Hereditary angioedema exacerbation,Chloasma,Drug interactions (e.g., anticonvulsants, antibiotics, St. John's Wort)
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Known or suspected pregnancy,Current or past history of thromboembolic disorders (e.g., DVT, PE),Cerebrovascular or coronary artery disease,Active liver disease or hepatic adenoma,Uncontrolled hypertension (BP >160/100 mm Hg),Diabetes mellitus with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura) in women >35,Breast cancer or other estrogen-sensitive neoplasms,Undiagnosed abnormal uterine bleeding,Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir,Severe renal insufficiency or adrenal insufficiency (due to drospirenone's K+-sparing diuretic effect),Smoking in women >35 years
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No specific food interactions. Grapefruit juice may increase estrogen levels, but clinical significance is not established. The iron tablets should be taken with food if gastrointestinal upset occurs; avoid taking with calcium-rich foods or beverages (e.g., milk) as they may reduce iron absorption.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
BLISOVI 24 FE (norethindrone/ethinyl estradiol) is contraindicated in pregnancy due to increased risk of fetal harm, including cardiovascular anomalies and neural tube defects during first trimester. No evidence of teratogenicity from inadvertent exposure, but risk of oral clefts and heart defects with first trimester use. Later trimester exposure may be associated with genitourinary anomalies and potentially metabolic effects.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio approximately 0.4-0.7. May reduce milk production, especially in early postpartum. Benefit-risk assessment required; consider alternative contraception for lactating women.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
No dose adjustment in pregnancy as drug is contraindicated. Pharmacokinetic changes in pregnancy (increased clearance, decreased protein binding) may reduce efficacy; not applicable due to contraindication.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
BLISOVI 24 FE is a combination oral contraceptive containing drospirenone and ethinyl estradiol, with ferrous fumarate as an iron supplement in the fourth week. The drospirenone component has anti-mineralocorticoid activity, which may cause mild potassium elevation; caution in patients with renal impairment or on potassium-sparing diuretics. Missed pills in week 1 warrant a backup method. The iron tablets are placebo for contraception; ensure patient does not mistake them for active pills.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one pill daily at the same time. The last 4 tablets in the pack are iron tablets, not active hormones; they do not provide contraception.,If you miss one active pill, take it as soon as remembered and continue the pack. If you miss two active pills in a row, take the last missed pill, discard the other, use backup contraception for 7 days.,Smoking increases risk of serious cardiovascular side effects, especially in women over 35. Avoid smoking while on this medication.,Inform your healthcare provider if you have kidney disease, liver disease, adrenal insufficiency, or if you take potassium-sparing diuretics (e.g., spironolactone) due to potential potassium elevation.,Common side effects include nausea, breast tenderness, headache, and spotting between periods. These often improve after a few cycles.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BLISOVI 24 FE vs ALYACEN 1/35, answered by our medical review team.
BLISOVI 24 FE is a Oral Contraceptive that works by Combination of ethinyl estradiol and drospirenone; primarily suppresses gonadotropins (FSH, LH) via negative feedback, preventing ovulation. Drospirenone has anti-mineralocorticoid and anti-androgenic activity.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BLISOVI 24 FE and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BLISOVI 24 FE is: One tablet orally once daily for 24 weeks, followed by placebo tablets for 4 weeks; each tablet contains 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol for 21 days, then 0.01 mg ethinyl estradiol for 3 days, then 2 tablets of 75 mg ferrous fumarate for 5 days.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BLISOVI 24 FE and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BLISOVI 24 FE is classified as Category C. BLISOVI 24 FE (norethindrone/ethinyl estradiol) is contraindicated in pregnancy due to increased risk of fetal harm, including cardiovascular anomalies and neural tube defects duri. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.